Freezing and transplanting ovarian tissue for young female cancer patients
Ovarian Tissue Cryopreservation and Subsequent Auto-Transplantation for Female
This study is testing if freezing and later transplanting ovarian tissue can help young female cancer patients preserve their ability to have children after treatment.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 100 (estimated) |
| Ages | 12 Years to 18 Years |
| Sex | Female |
| Sponsor | Chinese University of Hong Kong Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Hong Kong) |
| Trial ID | NCT06505057 on ClinicalTrials.gov |
What this trial studies
This study focuses on ovarian tissue cryopreservation as a method to preserve fertility in young female cancer patients who require immediate treatment that may harm their reproductive capabilities. The approach allows for the freezing of ovarian tissue without the need for ovarian stimulation, which can take time that these patients may not have. The study aims to develop this service locally to provide more options for fertility preservation among this vulnerable population. The research will also explore the outcomes of auto-transplantation of the cryopreserved tissue, particularly in patients who are prepubescent.
Who should consider this trial
Good fit: Ideal candidates are female cancer patients aged 0-35 who are at risk of losing their fertility due to their treatment.
Not a fit: Patients who are not undergoing oncologic therapies or those who are pregnant will not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly enhance fertility preservation options for young female cancer patients facing gonadotoxic treatments.
How similar studies have performed: While there have been successful cases of ovarian tissue transplantation, this specific approach for prepubescent patients is less explored, making it a novel initiative.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients aged from 0-35 years old and diagnosed with cancer e.g., leukaemia, myeloproliferative or myelodysplastic diseases, lymphoma, bone tumours, neurological neoplasms and sarcoma, Paediatric bone marrow transplant patients * Patients with any illness or who will undergo any type of treatment that may cause irreversible damage to their fertility, such as extensive abdominal surgery, high toxicity medication and treatments; * Patients suffering from hormone-sensitive malignancies who will undergo medical treatment, such as radiotherapy and chemotherapy that is liable to damage their ovaries and deter them from conception in the future. Exclusion Criteria: Patients with no anticipated oncologic therapies Patients who are pregnant Children with one ovary Children deemed high risk for perioperative complications Patients unable to provide consent/assent (i.e. significant psychiatric problems/cognitive delay) \-
Where this trial is running
Hong Kong
- Hong Kong Children's Hospital — Hong Kong, Hong Kong (Recruiting)
Study contacts
- Principal investigator: Jacqueline Pui Wah CHUNG, MBBS — Chinese University of Hong Kong
- Study coordinator: Elaine NG, MPhil
- Email: elaineng@cuhk.edu.hk
- Phone: 35052745
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.